AstraZeneca’s Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). EGPA is a rare, immune-mediated ...
(Alliance News) - AstraZeneca PLC on Wednesday announced Fasenra has been approved in the US to treat adult patients with eosinophilic granulomatosis with polyangiitis, or EGPA. The Cambridge, ...
(RTTNews) - AstraZeneca PLC (AZN, AZN.L) announced Wednesday that its Fasenra (benralizumab) has been approved in the US for the treatment of adult patients with eosinophilic granulomatosis with ...
Results that may be inaccessible to you are currently showing.